Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
Source: SeekingAlpha
2025-11-20 20:33:28 ET
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST...
Read the full article on Seeking Alpha
For further details see:
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
Lantern Pharma Inc.
NASDAQ: LTRN
LTRN Trading
-2.61% G/L:
$2.7172 Last:
7,690 Volume:
$2.71 Open:
LTRN Latest News
February 10, 2026 11:34:19 am
BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
February 10, 2026 08:45:00 am
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
January 20, 2026 10:36:15 am
BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
January 20, 2026 08:00:00 am
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
LTRN Stock Data
$32,826,282
9,358,007
0.05%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Dallas
